NEWRON PHARMACEUT. EO-20 (NP5) — Cash Flow Reinvestment Rate
NEWRON PHARMACEUT. EO-20 (NP5) has a Cash Flow Reinvestment Rate of 0.42x as of December 2025, reinvesting €13.66 Million (capex €48.00K plus investments €-13.62 Million) from operating cash flow of €32.35 Million. See NP5 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
NEWRON PHARMACEUT. EO-20 Cash Flow Reinvestment Rate (2025–2025)
Historical reinvestment intensity for NEWRON PHARMACEUT. EO-20 across 1 annual periods. For the full cash flow conversion analysis, see NP5 cash flow metrics.
Annual Cash Flow Reinvestment Rate for NEWRON PHARMACEUT. EO-20 (2025–2025)
Year-by-year capital reinvestment analysis for NEWRON PHARMACEUT. EO-20. See how financially flexible is NEWRON PHARMACEUT. EO-20 to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.42x | €13.66 Million | €32.35 Million | €48.00K | — |